Industry

FDA approves Ryzumvi eye drop for presbyopia

Healio Optometry3d ago1 min read

The FDA approved a supplemental new drug application for Ryzumvi, a preservative-free eye drop, for the treatment of presbyopia.“Presbyopia affects approximately 90% of Americans over age 45, making everyday activities like reading, using smartphones and working on computers increasingly difficult. Many patients rely on reading glasses or other corrective lenses, creating a significant need for convenient, noninvasive treatment options,” George Magrath, MD, MBA, MS, CEO of Opus Genetics, told Healio. “Phentolamine ophthalmic solution 0.75% offers a pharmacological alternative designed to

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has approved a supplemental new drug application for Ryzumvi (phentolamine ophthalmic solution 0.75%), a preservative-free eye drop now indicated for the treatment of presbyopia. This pharmacological option provides a noninvasive alternative to reading glasses for the approximately 90% of Americans over age 45 who experience difficulty with near-vision tasks.

Why It Matters

The approval of Ryzumvi adds a significant tool to the emerging category of pharmacological presbyopia treatments, addressing a nearly universal age-related condition. While reading glasses and contact lenses have long been the standard, there is a high demand for lifestyle-friendly, 'glasses-free' solutions for reading and digital device use. As a preservative-free formulation, Ryzumvi may offer a better safety and comfort profile for patients concerned about ocular surface health or those who already suffer from dry eye symptoms common in the presbyopic demographic.

Key Details

Ryzumvi is a phentolamine ophthalmic solution at a 0.75% concentration.
The medication is formulated as a preservative-free eye drop, reducing the risk of preservative-related ocular surface irritation.
The FDA approval was granted via a supplemental new drug application specifically for the presbyopia indication.
The treatment is designed to improve functional near vision for tasks such as smartphone use and reading without the need for corrective lenses.

Practice Implications

Eye care providers should consider Ryzumvi for patients over 45 who are seeking alternatives to reading glasses or multifocal contact lenses. The preservative-free nature of the drop makes it a particularly relevant option for patients with sensitive eyes or co-existing ocular surface disease. Clinicians will need to educate patients on the role of pharmacological pupil modulation as a convenient, noninvasive supplement to their current vision correction routine.

Who's Affected

OptometristsOphthalmologistsPresbyopic PatientsComprehensive Eye Care Providers

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.